Displaying drugs 8951 - 8975 of 9148 in total
rAAVrh74.MCK.GALGT2
Investigational
Nomlabofusp
Investigational
TOL2
TOL2 is a modified form of the acetylcholine receptor being investigated for the treatment of myasthenia gravis.
Investigational
Tominersen
Investigational
Autologous adipose derived mesenchymal stromal cells
Investigational
Autologous cord blood
Investigational
INT41
INT41 (also known as rAAV6-INT41) is a recombinant adeno-associated virus vector containing DNA encoding INT41 intrabody.
Investigational
RGX-181
RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene. Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Investigational
AVXS-301
AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene. It is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Investigational
HER-902
Investigational
CNM-Au8
Investigational
Human Embryonic Stem Cell-derived Astrocytes
Investigational
Palucorcel
Palucorcel is an investigational stem cell therapy consisting of human umbilical tissue-derived cells. Developed by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.
Investigational
RPI-MN
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
GALE-302
Investigational
C-Alpha-stx2
Investigational
Viralym-C
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
Investigational
ISIS-333611
Investigational
Recombinant human palmitoyl protein thioesterase-1
Investigational
Baloramotide
Investigational
PLX-R18
Investigational
GMI-1359
GMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.
Investigational
Displaying drugs 8951 - 8975 of 9148 in total